Simply put, the principle is based on preferentially delivering a fluorescent material, a fluorophore, to the target tissue, followed by exposing the operative field to excitation light of a particular wavelength that lies in the invisible spectrum. Excitation of the fluorophore results in emission of a different light, a phenomenon that is called fluorescence. Emitted light is either visible and is picked up by the naked eye, or invisible and requires a special camera to see.
During the last decade, the surgical literature has witnessed a persistently growing number of publications addressing this evolving technology. Most of them have investigated the use of the fluorophore indocyanine green (ICG), which is excited by near-infrared (NIR) light. Popularity of this light is due to its tissue penetration to a depth that exceeds the conventional white light as it may reach down to 1cm. It, thus, allows the real-time vision of the operator to reach beneath the surface, albeit for no more than a centimetre. Two other fluorophores are in common use. These are fluorescein and 5-aminolevulinic acid (5-ALA).
The technology made its best impact in the field of cancer surgery. In this field ensuring complete cancer excision, meanwhile reducing collateral damage is the sine qua non for success. Success with making cancers fluoresce is based on the fact that the leaky nature of tumour vessels allows a fluorophore to gain a higher concentration in its tissues. Among the different types of studied malignancies, two have shown that fluorescence guidance is of notable value. Removal of intracranial gliomas under 5-ALA guidance has demonstrated that the real extension of the tumour is likely to be beyond that identified by MRI (1). Equally good, several research articles have attested to the added value of ICG/NIR for precisely locating liver tumours, intraoperatively (2) . Furthermore, boosting precision of cancer localization can be achieved by selective targeting where the fluorophore is bound to a molecule that has avidity for certain neoplastic tissue. The new technology has also found its way for locating sentinel lymph nodes (SLN) in cases of breast cancer and melanoma surgery. Case series studies proved its feasibility and safety. It was also studied for accuracy either in its own or in combination with other modalities. A 2014 randomized controlled trial (4) compared blue dye with fluorescence technique for breast cancer SLN where ICG/NIR fluorescence proved to give a significantly higher detection rate.
Editorial
Outside the field of cancer surgery, the list of operative fluorescence guidance is long, yet two examples of popular operations are worth mentioning, namely cholecystectomy and intestinal resection. While intraoperative cholangiography (IOC) is the standard method for delineating bile duct anatomy at cholecystectomy, the technique is not perfect. It involves ionizing radiation and entails exhausting mental work in order to adapt the radiographic image to what the surgeon actually sees on a laparoscopy screen. Consequently, such adaptation is commonly inaccurate. Fluorescence guidance promises to fill this gap with its safety and real-time augmented visualization of the ducts. Multiple studies verified the efficacy and safety of ICG/NIR for ductal delineation. Others concluded that it could shorten operative time (5) while being easier to use and is less costly than IOC (6) . Further less expensive and simpler fluorescent technology using fluorescein and ultraviolet light has more recently evolved. As the emitted light is within the visible spectrum it requires no special cameras to detect. The technique proved to be 100% specific and 82.5% sensitive for locating bile duct (7).
While fluorescence-guided cholecystectomy is new, fluorescence for assessing intestinal viability dates back to the mid 20th century. An intravenously administered fluorophore will reach vascularized segments and will fluoresce under excitation light while non-vascularized segments will not. The technique would, thus, guide the surgeon to the extent of resection and helps judge viability of an anastomosis. With the recent technological advances, the use of this principle has been revived, particularly with robotic resection of rectal cancer, a site that is known for a notoriously high leakage rate. Initial reports revealed encouraging results (8,9).
Fluorescence-guided surgery suffers two weak points. The first is technical, which is limited penetration of the excitation light. Some may argue that this point might not be a significant obstacle because the surgeon will bring the tissue of interest closer to the surface during dissection. A more practical solution is combining fluorescence with another technique, e.g., ultrasound, Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) scan. The other weak point that actually slows down its routine use in surgical practice is that most of the relevant research is not of high evidence level. In fact, only a few randomized controlled trials were published. This is clearly a problem that will be solved with time, as more high-quality research will be generated.
The advantages of this technology certainly outnumber its disadvantages. The main one is the real-time augmentation of the surgeon's vision. The target becomes visually more prominent in the operative field. Other strong points include simplicity, fair efficacy and safety. In addition, it is relatively new and is; therefore, open to research and development. The expectation is that "fluorescence-guided surgery is here to stay and mature". 
